Polen Capital, an investment management company, released its “Polen Global Growth Strategy” third-quarter 2024 investor ...

Swiss biotech Alentis Therapeutics has secured $181.4 million, money that will be used to launch clinical trials for two ...

Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK ...

Novo Nordisk is expected to report third-quarter earnings on Wednesday. Stock up 8.55% in a year, 7.45% year-to-date.

Kepler Capital analyst David Evans maintained a Hold rating on Novo Nordisk (0QIU – Research Report) on November 6 and set a price target of DKK715.00. The company’s shares closed last ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Disruptive analytics’ Substack by Magnus Ofstad. In this article ...

Novo Nordisk (NVO) has released an update. Novo Nordisk has announced a significant transaction under its 2024 share repurchase program, ...

We recently compiled a list of the 8 Best European Stocks To Buy According to Hedge Funds. In this article, we are going to ...

Nektar Therapeutics is selling its Huntsville, Alabama, manufacturing plant and reagent supply business to private equity ...

Analysts have set 12-month price targets for Novo Nordisk, revealing an average target of $159.43, a high estimate of $160.00 ...

“Next year, the focus will shift to orals,” said Gareth Powell, head of health care at Polar Capital. His team has £3.6 ...

Novo Nordisk’s total revenue in the third quarter missed analysts’ expectations but sales of weight loss drug Wegovy exceeded the consensus forecast. Still, the Danish drugmaker narrowed its full-year ...